Similarly, a second consensus error grid with relaxed restrictions was designed for people with type 2 diabetes on insulin therapy since this population can potentially tolerate larger errors in the blood glucose value compared with people with T1D (Figure 1c). This evidence concerns the gene INS and type 1 diabetes mellitus.